Cardiovascular disease (CVD) is the major cause of death in the world. Clinical guidelines recommend the use of risk assessment tools (scores) to identify the CVD risk of each patient as the correct stratification of patients may significantly contribute to the optimization of the health care strategies. This work further explores the personalization of CVD risk assessment, supported on the evidence that a specific CVD risk assessment tool may have good performance within a given group of patients and might perform poorly within other groups. Two main personalization methods based on the proper creation of groups of patients are presented: i) clustering patients approach; ii) similarity measures approach. These two methodologies were validated in a Portuguese population (460 Acute Coronary Syndrome with non-ST segment elevation (ACS-NSTEMI) patients). The similarity measures approach had the best performance, achieving maximum values of sensitivity, specificity and geometric mean of, respectively, 77.7%, 63.2%, 69.7%. These values represent an enhancement in relation to the best performance obtained with current CVD risk assessment tools applied in clinical practice (78.5%, 53.2%, 64.4%).